BioSpace News Archive

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2022 financial results on Wednesday, April 27, 2022, prior to the market open.

Longboard Pharmaceuticals, Inc. today announced that single ascending dose and multiple ascending dose data from the Phase 1 study evaluating LP352 in healthy volunteers will be presented at the American Academy of Neurology.

Praxis Precision Medicines , Inc. today announced that data from its PRAX-944 essential tremor (ET) program will be presented at the upcoming 2022 American Academy of Neurology (AAN) Annual Meeting, which will take place in Seattle, Washington from April 2 – 7, 2022 and virtually from April 24 – 26, 2022.

The Public Health Agency of Canada continues to monitor COVID-19 epidemiological indicators to quickly detect, understand and communicate emerging issues of concern.

Paratek Pharmaceuticals, Inc. announced that on March 31, 2022, the Company granted stock options and restricted stock units to ten new employees of the Company.

Cytokinetics, Incorporated announced that on March 31, 2022 it granted stock options to purchase an aggregate of 165,600 shares of common stock to eighteen new employees, whose employment commenced in March 2022, as a material inducement to their employment.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company approved the grant of stock options to purchase an aggregate of 58,600 shares of Karyopharm’s common stock and an aggregate of 36,900 restricted stock units to six newly-hired employees.

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 89,400 shares of Syros common stock to three newly hired employees in connection with their commencement of employment with Syros.

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 295,000 shares of the company’s common stock to four new employees.

Natus Medical Incorporated, a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th.